GlobeNewswire

Integrity Implants Receives CE Mark for its Novel FlareHawk® Expandable Lumbar Interbody Fusion Device

Share

Spine surgeons throughout the European Union Economic Area (EEA)1 will soon have access to FlareHawk’s minimal insertion profile, multiplanar and endplate-conforming expansion, and maximum graft delivery

PALM BEACH GARDENS, Fla., June 23, 2021 (GLOBE NEWSWIRE) -- Integrity Implants Inc., the leader in Adaptive Geometry™ technology for innovative spine surgery solutions, today announced that it has received CE mark certification for its flagship FlareHawk Expandable Lumbar Interbody Fusion Device. FlareHawk launched in the United States in August 2016 and more than 8,500 FlareHawk devices have been implanted in more than 6,000 patients to date.

“CE mark further validates our belief that FlareHawk is the first expandable interbody solution that will have a true global reach,” said Chris Walsh, Co-Founder and CEO of Integrity Implants. “FlareHawk’s novel design and efficient manufacturing process enable access to the EU healthcare system. We are excited to be launching in several select European countries and initiating a prospective study with FlareHawk in the coming months. Our previously published data, which helped precipitate CE Mark clearance, is very strong data compared to that currently seen in both the expandable and TLIF/PLIF spaces.”

The uniqueness of the FlareHawk multidirectional interbody fusion cage called for a different approach than that used by many medical device manufacturers to demonstrate equivalence to other previously approved products. Instead, Integrity Implants compiled original retrospective clinical evidence data on FlareHawk’s performance and safety, including fusion rates, patient-reported outcome scores and adverse events.

“This data was pivotal in establishing evidence showing the safety and effectiveness of FlareHawk’s multidirectional expanding cage,” said the study’s principle investigator, Dom Coric, M.D., Chief of Spine Division at Atrium Healthcare’s Musculoskeletal Institute and neurosurgeon at Carolina Neurosurgery & Spine Associates in Charlotte, N.C. “FlareHawk has provided exceptional outcomes for my patients, and I’m happy to have played a part in helping this innovative product receive approval for the benefit of many more patients throughout the European Union.”

The data utilized in the study followed strict inclusion criteria and was drawn from participants with comorbidities often seen in the general patient population, including high BMI, diabetes, coronary heart disease, hypertension and a history of smoking. The study also only allowed allograft or autograft to help facilitate fusion as opposed to more expensive spinal biologics like BMP, DBM or other processed biologics. Among the 129 study patients, TLIF (51%) or PLIF (49%) surgery was performed on 171 levels. A minimally invasive approach was used in 88% of the cases.

Outcomes were impressive, with 97.4% of levels achieving fusion based on the well-respected Bridwell-Lenke grading classification. Additionally, there were no (0%) reported device-related adverse events, no (0%) observations of cage subsidence (defined as an overlap between the vertebral endplates and the device exceeding 25% of the device height), and only one case (1.7%) of observed device migration (defined as displacement of the device relative to the position within intra-operative or immediate post-operative images). More than 70% of patients also demonstrated clinically significant improvements in VAS leg and back pain scores.

“Patient-reported outcomes, including ODI and VAS for leg and back pain, were significantly improved during the last patient follow-up, an extremely important benefit in the constant quest for optimal patient outcomes and satisfaction with value-based spine procedures,” said Raphael Roybal, M.D., M.B.A., Director of The Spine Institute at Chatham Orthopaedics in Savannah, Ga. and co-author of the study. “The FlareHawk device has been transformational for my practice, especially during the past year, as it has allowed me to transition many cases to an outpatient setting that is safer for my patients and staff.”

Mark Grubb, M.D., a minimally invasive spine surgeon at Northeast Ohio Spine Center in Akron, Ohio and co-author of the paper, agreed: “FlareHawk’s small insertion profile and multidirectional expansion means I can treat the patient minimally invasively via a single position. The open architecture of the device also allows me to deliver the bone graft through the expanded FlareHawk cage and into the intervertebral space. This is a distinct improvement over other expandable products and represents another design aspect that I believe contributes to the favorable fusion rates seen with the FlareHawk device.”

In addition to receiving FDA clearance and CE mark approval, FlareHawk has also received approvals in Argentina, New Zealand, Taiwan and the United Arab Emirates.

About FlareHawk Expandable Lumbar Interbody Fusion System
The FlareHawk Interbody Fusion System is indicated for spinal intervertebral body fusion with autogenous bone graft and/or allogeneic bone graft composed of cancellous and/or corticocancellous bone in skeletally mature individuals with degenerative disc disease (DDD) at one or two contiguous levels from L2 to S1, following discectomy. DDD is defined as discogenic back pain with degeneration of the disc confirmed by history and radiographic studies. These patients should have at least six (6) months of non-operative treatment. Additionally, these patients may have up to Grade 1 spondylolisthesis or retrolisthesis at the involved level(s). FlareHawk system spacers are intended to be used with supplemental fixation instrumentation, which has been cleared for use in the lumbar spine.

About Integrity Implants Inc.

Integrity Implants, founded in 2016 by seasoned business partners and spine leaders Chris Walsh and Wyatt Geist, is a privately held medical device company headquartered in Palm Beach Gardens, Fla. The Company is dedicated to delivering innovative spine products and solutions to surgeons and their patients around the globe. Its proprietary Adaptive Geometry technology fundamentally respects a patient’s neural, vascular, bony and soft tissue anatomy, both during and after implantation. Learn more at www.integrityimplants.com.

1. The European Economic Area includes the EU: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden and the following countries: UK, Norway, Iceland, Liechtenstein, Switzerland and Turkey.

Media Contact: Brandy Craig
305-676-1679
bcraig@integrityimplants.com

A Media Snippet accompanying this announcement is available by clicking on the image or link below:

To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.


To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Beter Bed Holding announces the issue of 946,167 new ordinary shares23.7.2021 18:00:00 CEST | Press release

Beter Bed Holding N.V. (“BBH” ISIN NL0000339703), the Netherlands’ leading sleep specialist in retail, wholesale and B2B, announces the issue of 946,167 new ordinary shares of the Company against an issue price of € 6.82. The issue of shares is meant to remediate the impact on the Company’s solvency from the repayment of the perpetual loan, as announced in the interim results press release dated 21 July 2021. The net proceeds of the Offering will be used to strengthen our financial position and to provide the Company with the financial flexibility to accelerate the execution of its growth strategy 2025 as presented during the AGM of 12 May 2021. The increased attention for health and well-being, due to COVID-19, is expected to lead to increased demand for quality sleep as one of the three pillars of health. The investment program driven by our strategy is starting through the launch of a new shop format, subscription label Leazzzy, investments in data analytics and acceleration of onli

Arcadis reports transactions under its current share buyback program23.7.2021 12:00:00 CEST | Press release

Amsterdam, July 23, 2021 – Arcadis (EURONEXT: ARCAD), the leading global Design & Consultancy organization for natural and built assets, has repurchased 91.282 of its own shares in the period from 16 July up to and including 22 July 2021 at an average price of €34.59. The consideration of this repurchase was €3.2 million. The repurchase is in accordance with the share buyback program to cover existing obligations under employee incentive plans and to cover commitments for stock dividend, as announced on 19 February 2021. The total number of shares repurchased under this program to date is 1.7 million shares for a total consideration of €56.0 million. For more detailed information see: https://www.arcadis.com/en/global/investors/share-information/share-buyback-program/ -End- Improving quality of life FOR FURTHER INFORMATION PLEASE CONTACT: ARCADIS INVESTOR RELATIONS Jurgen Pullens Mobile: +31 6 51599483 E-mail: jurgen.pullens@arcadis.com ABOUT ARCADIS Arcadis is the leading global desig

Vaisala Corporation Half Year Financial Report January–June 202123.7.2021 08:00:00 CEST | Press release

Vaisala Corporation Half Year Financial Report July 23, 2021 at 9.00 a.m. (EEST) Vaisala Corporation Half Year Financial Report January–June2021 Excellent growth continued in second quarter Secondquarter 2021 highlights Orders received EUR 120.1 (95.9) million, increase 25%Order book at the end of the period EUR 165.3 (145.3) million, increase 14%Net sales EUR 109.5 (91.4) million, increase 20%Operating result (EBIT) EUR 10.9 (7.9) million, 10.0 (8.7) % 0f net salesEarnings per share EUR 0.25 (0.16)Cash flow from operating activities EUR 11.1 (-1.1) million January–June 2021 highlights Orders received EUR 226.3 (185.6) million, increase 22%Net sales EUR 201.5 (178.6) million, increase 13%Operating result (EBIT) EUR 19.0 (13.1) million, 9.5 (7.3) % 0f net salesEarnings per share EUR 0.43 (0.27)Cash flow from operating activities EUR 29.4 (4.2) million Market development and businessoutlook for 2021 Market for high-end industrial instruments is expected to continue growth after strong re

FLOW TRADERS Q221 RESULTS23.7.2021 07:30:00 CEST | Press release

FLOW TRADERS Q221 RESULTS Amsterdam, the Netherlands - Flow Traders N.V. (Euronext: FLOW) announces its unaudited Q221 results and 2021 Half Year report. Highlights Market ETP Value Traded decreased 14% quarter-on-quarter and decreased 14% H121 vs H120Flow Traders ETP Value Traded decreased 15% quarter-on-quarter and decreased 6% H121 vs H120Flow Traders recorded NTI of €94.4m in Q221 reflecting a more normalised market environment. This compares to NTI of €142.2m in Q121 and €229.9m in Q220. H121 NTI was €236.6m vs €724.8m in H120Total operating expenses of €54.1m incurred in Q221 which includes €0.6m of one-off COVID-19 and business continuity plan-related expenses577 FTEs as at 30 June 2021 compared to 566 FTEs as at 31 March 2021Q221 EBITDA reached €40.3m with a margin of 43% contributing to H121 EBITDA of €119.6m with a margin of 51%Q221 Net Profit amounted to €28.7m with basic EPS of €0.66. H121 Net Profit amounted to €90.2m with basic EPS of €2.05IFR/IFD came into force on 26 Ju

Signify reports second quarter sales of EUR 1.6 billion, operational profitability of 10.9% and a free cash flow of EUR 104 million23.7.2021 07:00:00 CEST | Press release

Press Release July 23, 2021 Signify reports second quarter sales of EUR 1.6 billion, operational profitability of 10.9% and a free cash flow of EUR 104 million Second quarter 20211 Signify's installed base of connected light points increased from 83 million in Q1 21 to 862 million in Q2 21 Sales of EUR 1,609 million; 9.6% nominal sales growth and CSG of 14.1%LED-based sales represented 82% of total sales (Q2 2020: 80%)Adj. EBITA margin improved by 190 bps to 10.9%Net income increased to EUR 82 million (Q2 20: EUR 81 million)Free cash flow of EUR 104 million (Q2 20: EUR 158 million)Net debt/EBITDA ratio of 1.7x (Q2 20: 2.4x) Eindhoven, the Netherlands – Signify (Euronext: LIGHT), the world leader in lighting, today announced the company’s second quarter 2021 results. “In the second quarter we saw an acceleration of the pace of recovery in comparison to the first three months of the year. We successfully executed our strategy as demand for our connected lighting offers and our growth pla

Norsk Hydro: Andre kvartal 2021 – Rekordresultater og fortsatt positivt markedssentiment23.7.2021 07:00:00 CEST | Pressemelding

Norsk Hydro ASA rapporterte en justert EBITDA på 6.598 millioner kroner i andre kvartal 2021, en økning fra 2,794 millioner kroner i samme kvartal i fjor. Fortsatt oppgang i verdensøkonomien bidrar til økt etterspørsel etter aluminium og aluminiumprodukter. Forretningsområdene Hydro Aluminium Metal og Hydro Extrusions rapporterte rekordresultater for kvartalet. Rekordresultat i Aluminium Metal på grunnlag av økte priser og produktpremier på LMERobust drift, forbedringsprogrammet foran skjema Sterke prestasjoner i Extrusions og framdrift i vekstprosjekterStyrking av bærekraftposisjon med investeringer for vekst i resirkuleringSalget av forretningsområdet Hydro Rolling til KPS Capital Partners fullført Høyere all-in metallpriser og volumer i Aluminium Metal, bedre marginer og volumer i Extrusions og bedre resultater fra Hydro Energy bidro positivt til justert EBITDA. Disse positive elementene ble delvis utliknet av høyere råvarekostnader oppstrøms og negative valutaeffekter. Den globale

Norsk Hydro: Second quarter 2021 - Record results and continued positive market sentiment23.7.2021 07:00:00 CEST | Press release

Norsk Hydro ASA posted second-quarter 2021 adjusted EBITDA of NOK 6,598 million, up from NOK 2,794 million in the same quarter last year. Continued global economic recovery is supporting increased demand for aluminium and aluminium products. Hydro Aluminium Metal and Hydro Extrusions business areas reported record quarterly results. Record result in Aluminium Metal supported by LME prices and premiumsRobust operations, improvement program ahead of plan Strong performance in Extrusions and progress on growth initiativesStrengthening sustainability position with growth investments in recyclingSale of Hydro Rolling business area to KPS Capital Partners completed Higher all-in metal prices and volumes in Aluminium Metal, improved margins and volumes in Extrusions, and better results from Hydro Energy contributed positively to adjusted EBITDA. These positive elements were partly offset by higher raw material costs upstream and negative currency effects. The second quarter saw a continuation